Limits...
Fetuin-A as a predicator of sarcopenic left ventricular dysfunction.

Chang WT, Tsai WC, Wu CH, Lee YW, Tai YL, Li YH, Tsai LM, Chen JH, Liu PY - Sci Rep (2015)

Bottom Line: Patients with S-LVD showed relatively reduced systolic heart function, higher end-diastolic pressure and a higher FetA level (all p < 0.001) than did those with sarcopenia but without LV dysfunction (S-NLVD).Multivariable logistic regression showed that older age, impaired diastolic function, and higher FetA levels were significantly associated with S-LVD.In conclusion, we found that FetA was significantly higher in elderly patients with sarcopenia, which was associated with impaired diastolic and systolic functions.

View Article: PubMed Central - PubMed

Affiliation: 1] Division of Cardiology, Internal Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan [2] Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan [3] Division of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan, Taiwan.

ABSTRACT
Sarcopenia is an aging condition involving low muscle mass and function. Fetuin-A (FetA) appears to be a factor for body composition remodeling. We hypothesized that age increases FetA levels and deteriorates the myocardial function by affecting diastolic function, especially in people with sarcopenia. We enrolled 541 asymptomatic elderly (≥ 65 years) patients. Compared with non-sarcopenic population, FetA levels were significantly elevated in the ninety-two (17%) patients (79 ± 6 years; male: 34.7%) diagnosed with sarcopenia (621.1 ± 140.7 vs. 697.3 ± 179.6 μg/ml, < 0.001). Sarcopenic left ventricular dysfunction (S-LVD) was defined by the coexistence of sarcopenia and systolic impairment (LVEF < 50%) and 23 (4.3%) of them met the criteria. Patients with S-LVD showed relatively reduced systolic heart function, higher end-diastolic pressure and a higher FetA level (all p < 0.001) than did those with sarcopenia but without LV dysfunction (S-NLVD). Conversely, in the group without sarcopenia, FetA levels were similar regardless of systolic function. Multivariable logistic regression showed that older age, impaired diastolic function, and higher FetA levels were significantly associated with S-LVD. In conclusion, we found that FetA was significantly higher in elderly patients with sarcopenia, which was associated with impaired diastolic and systolic functions.

No MeSH data available.


Related in: MedlinePlus

Higher level of fetuin-A (FetA) was associated with sarcopenic subjects, especially with systolic dysfunction.(A) serum levels of FetA (μg/mL) and (B) diastolic dysfunction (E′ < 8 cm/s and E/E′ > 8) prevalence rate in the groups without sarcopenia and left ventricular systolic dysfunction (NS-NLVD), without sarcopenia but with left ventricular systolic dysfunction (NS-LVD), with sarcopenia but with non- left ventricular systolic dysfunction (S-NLVD), and with sarcopenia and left ventricular systolic dysfunction (S-LVD). Abbreviations: FetA, fetuin-A; E/E′, ratio of early transmitral flow velocity (E) to early diastolic mitral annulus velocity (e′). *p < 0.001; **p < 0.01.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4498243&req=5

f1: Higher level of fetuin-A (FetA) was associated with sarcopenic subjects, especially with systolic dysfunction.(A) serum levels of FetA (μg/mL) and (B) diastolic dysfunction (E′ < 8 cm/s and E/E′ > 8) prevalence rate in the groups without sarcopenia and left ventricular systolic dysfunction (NS-NLVD), without sarcopenia but with left ventricular systolic dysfunction (NS-LVD), with sarcopenia but with non- left ventricular systolic dysfunction (S-NLVD), and with sarcopenia and left ventricular systolic dysfunction (S-LVD). Abbreviations: FetA, fetuin-A; E/E′, ratio of early transmitral flow velocity (E) to early diastolic mitral annulus velocity (e′). *p < 0.001; **p < 0.01.

Mentions: In this cohort, 23 (25%) of the 92 patients with sarcopenia met the S-LVD criteria (Table 2). Significantly more patients in the S-LVD subgroup were male (p < 0.001) and had stroke, coronary artery disease (CAD), and arrhythmia prevalence rates that were not significantly different. Echocardiography showed a non-significantly higher left ventricular mass index (LVMI) and a significantly higher estimated end-diastolic pressure (E/E′) in the S-LVD subgroup, which might indicate stiffness of the myocardium or diastolic dysfunction. The serologic profiles showed significantly higher HDL-C (p = 0.034) and FetA (p < 0.001) levels in the S-LVD subgroup patients. They had the highest E/E′, FetA levels and the lowest E′ of the 4 subgroups. In the group with sarcopenia, FetA was significantly (p < 0.001) higher in the S-LVD group (788.2 ± 170.2 μg/ml) than in the S-NLVD group (664.3 ± 163.8), but the difference of FetA levels was not significant in the non-sarcopenia group (Fig. 1A).


Fetuin-A as a predicator of sarcopenic left ventricular dysfunction.

Chang WT, Tsai WC, Wu CH, Lee YW, Tai YL, Li YH, Tsai LM, Chen JH, Liu PY - Sci Rep (2015)

Higher level of fetuin-A (FetA) was associated with sarcopenic subjects, especially with systolic dysfunction.(A) serum levels of FetA (μg/mL) and (B) diastolic dysfunction (E′ < 8 cm/s and E/E′ > 8) prevalence rate in the groups without sarcopenia and left ventricular systolic dysfunction (NS-NLVD), without sarcopenia but with left ventricular systolic dysfunction (NS-LVD), with sarcopenia but with non- left ventricular systolic dysfunction (S-NLVD), and with sarcopenia and left ventricular systolic dysfunction (S-LVD). Abbreviations: FetA, fetuin-A; E/E′, ratio of early transmitral flow velocity (E) to early diastolic mitral annulus velocity (e′). *p < 0.001; **p < 0.01.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4498243&req=5

f1: Higher level of fetuin-A (FetA) was associated with sarcopenic subjects, especially with systolic dysfunction.(A) serum levels of FetA (μg/mL) and (B) diastolic dysfunction (E′ < 8 cm/s and E/E′ > 8) prevalence rate in the groups without sarcopenia and left ventricular systolic dysfunction (NS-NLVD), without sarcopenia but with left ventricular systolic dysfunction (NS-LVD), with sarcopenia but with non- left ventricular systolic dysfunction (S-NLVD), and with sarcopenia and left ventricular systolic dysfunction (S-LVD). Abbreviations: FetA, fetuin-A; E/E′, ratio of early transmitral flow velocity (E) to early diastolic mitral annulus velocity (e′). *p < 0.001; **p < 0.01.
Mentions: In this cohort, 23 (25%) of the 92 patients with sarcopenia met the S-LVD criteria (Table 2). Significantly more patients in the S-LVD subgroup were male (p < 0.001) and had stroke, coronary artery disease (CAD), and arrhythmia prevalence rates that were not significantly different. Echocardiography showed a non-significantly higher left ventricular mass index (LVMI) and a significantly higher estimated end-diastolic pressure (E/E′) in the S-LVD subgroup, which might indicate stiffness of the myocardium or diastolic dysfunction. The serologic profiles showed significantly higher HDL-C (p = 0.034) and FetA (p < 0.001) levels in the S-LVD subgroup patients. They had the highest E/E′, FetA levels and the lowest E′ of the 4 subgroups. In the group with sarcopenia, FetA was significantly (p < 0.001) higher in the S-LVD group (788.2 ± 170.2 μg/ml) than in the S-NLVD group (664.3 ± 163.8), but the difference of FetA levels was not significant in the non-sarcopenia group (Fig. 1A).

Bottom Line: Patients with S-LVD showed relatively reduced systolic heart function, higher end-diastolic pressure and a higher FetA level (all p < 0.001) than did those with sarcopenia but without LV dysfunction (S-NLVD).Multivariable logistic regression showed that older age, impaired diastolic function, and higher FetA levels were significantly associated with S-LVD.In conclusion, we found that FetA was significantly higher in elderly patients with sarcopenia, which was associated with impaired diastolic and systolic functions.

View Article: PubMed Central - PubMed

Affiliation: 1] Division of Cardiology, Internal Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan [2] Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan [3] Division of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan, Taiwan.

ABSTRACT
Sarcopenia is an aging condition involving low muscle mass and function. Fetuin-A (FetA) appears to be a factor for body composition remodeling. We hypothesized that age increases FetA levels and deteriorates the myocardial function by affecting diastolic function, especially in people with sarcopenia. We enrolled 541 asymptomatic elderly (≥ 65 years) patients. Compared with non-sarcopenic population, FetA levels were significantly elevated in the ninety-two (17%) patients (79 ± 6 years; male: 34.7%) diagnosed with sarcopenia (621.1 ± 140.7 vs. 697.3 ± 179.6 μg/ml, < 0.001). Sarcopenic left ventricular dysfunction (S-LVD) was defined by the coexistence of sarcopenia and systolic impairment (LVEF < 50%) and 23 (4.3%) of them met the criteria. Patients with S-LVD showed relatively reduced systolic heart function, higher end-diastolic pressure and a higher FetA level (all p < 0.001) than did those with sarcopenia but without LV dysfunction (S-NLVD). Conversely, in the group without sarcopenia, FetA levels were similar regardless of systolic function. Multivariable logistic regression showed that older age, impaired diastolic function, and higher FetA levels were significantly associated with S-LVD. In conclusion, we found that FetA was significantly higher in elderly patients with sarcopenia, which was associated with impaired diastolic and systolic functions.

No MeSH data available.


Related in: MedlinePlus